<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM"><PMID Version="2">31686397</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Molecular Mechanisms and Therapeutics for SBMA/Kennedy's Disease.</ArticleTitle><Pagination><StartPage>928</StartPage><EndPage>947</EndPage><MedlinePgn>928-947</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-019-00790-9</ELocationID><Abstract><AbstractText>Spinal and bulbar muscular atrophy (SBMA) is a neuromuscular disease caused by a polyglutamine (polyQ) expansion in the androgen receptor (AR). Despite the fact that the monogenic cause of SBMA has been known for nearly 3 decades, there is no effective treatment for this disease, underscoring the complexity of the pathogenic mechanisms that lead to a loss of motor neurons and muscle in SBMA patients. In the current review, we provide an overview of the system-wide clinical features of SBMA, summarize the structure and function of the AR, discuss both gain-of-function and loss-of-function mechanisms of toxicity caused by polyQ-expanded AR, and describe the cell and animal models utilized in the study of SBMA. Additionally, we summarize previously conducted clinical trials which, despite being based on positive results from preclinical studies, proved to be largely ineffective in the treatment of SBMA; nonetheless, these studies provide important insights as researchers develop the next generation of therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Frederick J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Thomas Jefferson University, 411E Jefferson Alumni Hall, 1020 Locust Street, Philadelphia, Pennsylvania, 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merry</LastName><ForeName>Diane E</ForeName><Initials>DE</Initials><Identifier Source="ORCID">0000-0003-0521-1002</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Thomas Jefferson University, 411E Jefferson Alumni Hall, 1020 Locust Street, Philadelphia, Pennsylvania, 19107, USA. diane.merry@jefferson.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C410798">AR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance></Chemical><Chemical><RegistryNumber>26700-71-0</RegistryNumber><NameOfSubstance UI="C097188">polyglutamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Polyglutamine</Keyword><Keyword MajorTopicYN="N">androgen receptor</Keyword><Keyword MajorTopicYN="N">motor neuron</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">spinal and bulbar muscular atrophy.</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31686397</ArticleId><ArticleId IdType="pmc">PMC6985201</ArticleId><ArticleId IdType="doi">10.1007/s13311-019-00790-9</ArticleId><ArticleId IdType="pii">10.1007/s13311-019-00790-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology. 1968;18(7):671&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">4233749</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352(6330):77&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Atsuta N, Watanabe H, Ito M, Banno H, Suzuki K, Katsuno M, et al. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain. 2006;129(Pt 6):1446&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">16621916</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Rhodes LE, Kokkinis AD, White MJ, Watts CA, Auh S, Jeffries NO, et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol. 2011;10(2):140&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056353</ArticleId><ArticleId IdType="pubmed">21216197</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobue G, Hashizume Y, Mukai E, Hirayama M, Mitsuma T, Takahashi A. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain. 1989;112(Pt 1):209&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">2917278</ArticleId></ArticleIdList></Reference><Reference><Citation>Amato AA, Prior TW, Barohn RJ, Snyder P, Papp A, Mendell JR. Kennedy&#x2019;s disease: a clinicopathologic correlation with mutations in the androgen receptor gene. Neurology. 1993;43(4):791&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8469342</ArticleId></ArticleIdList></Reference><Reference><Citation>Banno H, Katsuno M, Suzuki K, Tanaka F, Sobue G. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy (SBMA) Cell Tissue Res. 2012;349(1):313&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22476656</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes CJ, Ling SC, Guo LT, Hung G, Tsunemi T, Ly L, et al. Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron. 2014;82(2):295&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4096235</ArticleId><ArticleId IdType="pubmed">24742458</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorar&#xf9; G, D'Ascenzo C, Polo A, Palmieri A, Baggio L, Vergani L, et al. Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. J Neurol Sci. 2008;264(1&#x2013;2):100&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17854832</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Waza M, Banno H, Suzuki K, Tanaka F, et al. Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA) Exp Neurol. 2006;200(1):8&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">16513111</ArticleId></ArticleIdList></Reference><Reference><Citation>Chahin N, Sorenson EJ. Serum creatine kinase levels in spinobulbar muscular atrophy and amyotrophic lateral sclerosis. Muscle Nerve. 2009;40(1):126&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19533663</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G, Bertolin C, Da Re E, Volpe M, Zara G, Pegoraro E, et al. Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients. J Neurol Neurosurg Psychiatry. 2016;87(8):810&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4975824</ArticleId><ArticleId IdType="pubmed">26503015</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner CL, Griffin JE, Wilson JD, Jacobs LD, Murray KR, Fischbeck KH, et al. X-linked spinomuscular atrophy: a kindred with associated abnormal androgen receptor binding. Neurology. 1992;42(11):2181&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">1436532</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes LE, Freeman BK, Auh S, Kokkinis AD, La Pean A, Chen C, et al. Clinical features of spinal and bulbar muscular atrophy. Brain. 2009;132(Pt 12):3242&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2792370</ArticleId><ArticleId IdType="pubmed">19846582</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejager S, Bry-Gauillard H, Bruckert E, Eymard B, Salachas F, LeGuern E, et al. A comprehensive endocrine description of Kennedy&#x2019;s disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab. 2002;87(8):3893&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">12161529</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmann AO. Molecular basis of androgen insensitivity. Mol Cell Endocrinol. 2001;179(1&#x2013;2):105&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11420135</ArticleId></ArticleIdList></Reference><Reference><Citation>Koritsiadis G, Stravodimos K, Mitropoulos D, Doumanis G, Fokitis I, Koritsiadis S, et al. Androgens and bladder outlet obstruction: a correlation with pressure-flow variables in a preliminary study. BJU Int. 2008;101(12):1542&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18294304</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Miwa S, Kobayashi Y, Merry DE, Yamamoto M, Tanaka F, et al. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol. 1998;44(2):249&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">9708548</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Sobue G, Doyu M, Mukai E, Hashizume Y, Mitsuma T. Primary sensory neurons in X-linked recessive bulbospinal neuropathy: histopathology and androgen receptor gene expression. Muscle Nerve. 1995;18(3):301&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7870107</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding AE, Thomas PK, Baraitser M, Bradbury PG, Morgan-Hughes JA, Ponsford JR. X-linked recessive bulbospinal neuronopathy: a report of ten cases. J Neurol Neurosurg Psychiatry. 1982;45(11):1012&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC491638</ArticleId><ArticleId IdType="pubmed">6890989</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney RK, Aminoff MJ, So YT. Clinical and electrodiagnostic features of X-linked recessive bulbospinal neuronopathy. Neurology. 1991;41(6):823&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2046924</ArticleId></ArticleIdList></Reference><Reference><Citation>Polo A, Teatini F, D'Anna S, Manganotti P, Salviati A, Dallapiccola B, et al. Sensory involvement in X-linked spino-bulbar muscular atrophy (Kennedy&#x2019;s syndrome): an electrophysiological study. J Neurol. 1996;243(5):388&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">8741078</ArticleId></ArticleIdList></Reference><Reference><Citation>Kachi T, Sobue G, Sobue I. Central motor and sensory conduction in X-linked recessive bulbospinal neuronopathy. J Neurol Neurosurg Psychiatry. 1992;55(5):394&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC489083</ArticleId><ArticleId IdType="pubmed">1318357</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperfeld AD, Karitzky J, Brummer D, Schreiber H, H&#xe4;ussler J, Ludolph AC, et al. X-linked bulbospinal neuronopathy: Kennedy disease. Arch Neurol. 2002;59(12):1921&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12470181</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonini G, Gragnani F, Romaniello A, Pennisi EM, Morino S, Ceschin V, et al. Sensory involvement in spinal-bulbar muscular atrophy (Kennedy&#x2019;s disease) Muscle Nerve. 2000;23(2):252&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10639619</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrante MA, Wilbourn AJ. The characteristic electrodiagnostic features of Kennedy&#x2019;s disease. Muscle Nerve. 1997;20(3):323&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052811</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidetti D, Vescovini E, Motti L, Ghidoni E, Gemignani F, Marbini A, et al. X-linked bulbar and spinal muscular atrophy, or Kennedy disease: clinical, neurophysiological, neuropathological, neuropsychological and molecular study of a large family. J Neurol Sci. 1996;135(2):140&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8867070</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K, Katsuno M, Banno H, Takeuchi Y, Atsuta N, Ito M, et al. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA. Brain. 2008;131(Pt 1):229&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">18056738</ArticleId></ArticleIdList></Reference><Reference><Citation>Manganelli F, Iodice V, Provitera V, Pisciotta C, Nolano M, Perretti A, et al. Small-fiber involvement in spinobulbar muscular atrophy (Kennedy&#x2019;s disease) Muscle Nerve. 2007;36(6):816&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">17691102</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, Nirmalananthan N, Masset L, Skorupinska I, Collins T, Cortese A, et al. Correlation of clinical and molecular features in spinal bulbar muscular atrophy. Neurology. 2014;82(23):2077&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4075620</ArticleId><ArticleId IdType="pubmed">24814851</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariotti C, Castellotti B, Pareyson D, Testa D, Eoli M, Antozzi C, et al. Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. Neuromuscul Disord. 2000;10(6):391&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10899444</ArticleId></ArticleIdList></Reference><Reference><Citation>Guber RD, Takyar V, Kokkinis A, Fox DA, Alao H, Kats I, et al. Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy. Neurology. 2017;89(24):2481&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5729799</ArticleId><ArticleId IdType="pubmed">29142082</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatsuji H, Araki A, Hashizume A, Hijikata Y, Yamada S, Inagaki T, et al. Correlation of insulin resistance and motor function in spinal and bulbar muscular atrophy. J Neurol. 2017;264(5):839&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">28229243</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm A, Hirsch S, Volk AE, Grehl T, Grosskreutz J, Hanisch F, et al. The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy. J Neurol. 2018;265(5):1026&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">29464380</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin HY, Yu IC, Wang RS, Chen YT, Liu NC, Altuwaijri S, et al. Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology. 2008;47(6):1924&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">18449947</ArticleId></ArticleIdList></Reference><Reference><Citation>Soukup GR, Sperfeld AD, Uttner I, Karitzky J, Ludolph AC, Kassubek J, et al. Frontotemporal cognitive function in X-linked spinal and bulbar muscular atrophy (SBMA): a controlled neuropsychological study of 20 patients. J Neurol. 2009;256(11):1869&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">19572162</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasper E, Wegrzyn M, Marx I, Korp C, Kress W, Benecke R, et al. Minor cognitive disturbances in X-linked spinal and bulbar muscular atrophy, Kennedy&#x2019;s disease. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(1&#x2013;2):15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">24200287</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Rosa E, Sorar&#xf9; G, Kleinbub JR, Calvo V, Vallesi A, Querin G, et al. Theory of mind, empathy and neuropsychological functioning in X-linked spinal and bulbar muscular atrophy: a controlled study of 20 patients. J Neurol. 2015;262(2):394&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">25408365</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai TH, Liu RS, Yang BH, Wang PS, Lin KP, Lee YC, et al. Cerebral involvement in spinal and bulbar muscular atrophy (Kennedy&#x2019;s disease): a pilot study of PET. J Neurol Sci. 2013;335(1&#x2013;2):139&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">24120273</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassubek J, Juengling FD, Sperfeld AD. Widespread white matter changes in Kennedy disease: a voxel based morphometry study. J Neurol Neurosurg Psychiatry. 2007;78(11):1209&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117581</ArticleId><ArticleId IdType="pubmed">17332050</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcato S, Kleinbub JR, Querin G, Pick E, Martinelli I, Bertolin C, et al. Unimpaired neuropsychological performance and enhanced memory recall in patients with SBMA: a large sample comparative study. Sci Rep. 2018;8(1):13627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6134140</ArticleId><ArticleId IdType="pubmed">30206283</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G, Melacini P, D'Ascenzo C, Morandi L, Mazzini L, Silani V, et al. No evidence of cardiomyopathy in spinal and bulbar muscular atrophy. Acta Neurol Scand. 2013;128(6):e30&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">23679084</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki K, Nakanishi H, Nakamura T, Atsuta N, Yamada S, Hijikata Y, et al. Myotonia-like symptoms in a patient with spinal and bulbar muscular atrophy. Neuromuscul Disord. 2015;25(11):913&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">26363965</ArticleId></ArticleIdList></Reference><Reference><Citation>Romigi A, Liguori C, Placidi F, Albanese M, Izzi F, Uasone E, et al. Sleep disorders in spinal and bulbar muscular atrophy (Kennedy&#x2019;s disease): a controlled polysomnographic and self-reported questionnaires study. J Neurol. 2014;261(5):889&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">24590405</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumner CJ, Fischbeck KH. Jaw drop in Kennedy&#x2019;s disease. Neurology. 2002;59(9):1471&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">12427914</ArticleId></ArticleIdList></Reference><Reference><Citation>Praline J, Guennoc AM, Malinge MC, de Toffol B, Corcia P. Pure bulbar motor neuron involvement linked to an abnormal CAG repeat expansion in the androgen receptor gene. Amyotroph Lateral Scler. 2008;9(1):40&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">17852020</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunseich C, Kats IR, Bott LC, Rinaldi C, Kokkinis A, Fox D, et al. Early onset and novel features in a spinal and bulbar muscular atrophy patient with a 68 CAG repeat. Neuromuscul Disord. 2014;24(11):978&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252652</ArticleId><ArticleId IdType="pubmed">25047668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni W, Chen S, Qiao K, Wang N, Wu ZY. Genotype-phenotype correlation in Chinese patients with spinal and bulbar muscular atrophy. PLoS One. 2015;10(3):e0122279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4374859</ArticleId><ArticleId IdType="pubmed">25811990</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinnreich M, Sorenson EJ, Klein CJ. Neurologic course, endocrine dysfunction and triplet repeat size in spinal bulbar muscular atrophy. Can J Neurol Sci. 2004;31(3):378&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">15376484</ArticleId></ArticleIdList></Reference><Reference><Citation>Igarashi S, Tanno Y, Onodera O, Yamazaki M, Sato S, Ishikawa A, et al. Strong correlation between the number of CAG repeats in androgen receptor genes and the clinical onset of features of spinal and bulbar muscular atrophy. Neurology. 1992;42(12):2300&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">1461383</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Lim YM, Lee EJ, Oh YJ, Kim KK. Correlation between the CAG repeat size and electrophysiological findings in patients with spinal and bulbar muscular atrophy. Muscle Nerve. 2018;57(4):683&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">28972672</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson-Rechavi M, Carpentier AS, Duffraisse M, Laudet V. How many nuclear hormone receptors are there in the human genome? Trends Genet. 2001;17(10):554&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11585645</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmann AO, Faber PW, van Rooij HC, Kuiper GG, Ris C, Klaassen P, et al. The human androgen receptor: domain structure, genomic organization and regulation of expression. J Steroid Biochem. 1989;34(1&#x2013;6):307&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">2626022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavery DN, McEwan IJ. Structural characterization of the native NH2-terminal transactivation domain of the human androgen receptor: a collapsed disordered conformation underlies structural plasticity and protein-induced folding. Biochemistry. 2008;47(11):3360&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18284208</ArticleId></ArticleIdList></Reference><Reference><Citation>Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007;28(7):778&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">17940184</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R, Betney R, Li J, Thompson EB, McEwan IJ. Induced alpha-helix structure in AF1 of the androgen receptor upon binding transcription factor TFIIF. Biochemistry. 2004;43(11):3008&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023052</ArticleId></ArticleIdList></Reference><Reference><Citation>Langley E, Zhou ZX, Wilson EM. Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem. 1995;270(50):29983&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">8530400</ArticleId></ArticleIdList></Reference><Reference><Citation>He B, Gampe RT, Kole AJ, Hnat AT, Stanley TB, An G, et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell. 2004;16(3):425&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">15525515</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajpai P, Koc E, Sonpavde G, Singh R, Singh KK. Mitochondrial localization, import, and mitochondrial function of the androgen receptor. J Biol Chem. 2019;294(16):6621&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6484137</ArticleId><ArticleId IdType="pubmed">30792308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan S, Harmison GG, Meyertholen K, Pennuto M, Burnett BG, Fischbeck KH. Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Hum Mol Genet. 2009;18(1):27&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2644643</ArticleId><ArticleId IdType="pubmed">18824496</ArticleId></ArticleIdList></Reference><Reference><Citation>Beauchemin AM, Gottlieb B, Beitel LK, Elhaji YA, Pinsky L, Trifiro MA. Cytochrome c oxidase subunit Vb interacts with human androgen receptor: a potential mechanism for neurotoxicity in spinobulbar muscular atrophy. Brain Res Bull. 2001;56(3&#x2013;4):285&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">11719263</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT. Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci U S A. 2004;101(14):4758&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC387321</ArticleId><ArticleId IdType="pubmed">15037741</ArticleId></ArticleIdList></Reference><Reference><Citation>Lallous N, Dalal K, Cherkasov A, Rennie PS. Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer. Int J Mol Sci. 2013;14(6):12496&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3709796</ArticleId><ArticleId IdType="pubmed">23771019</ArticleId></ArticleIdList></Reference><Reference><Citation>Helsen C, Dubois V, Verfaillie A, Young J, Trekels M, Vancraenenbroeck R, et al. Evidence for DNA-binding domain&#x2013;ligand-binding domain communications in the androgen receptor. Mol Cell Biol. 2012;32(15):3033&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3434514</ArticleId><ArticleId IdType="pubmed">22645304</ArticleId></ArticleIdList></Reference><Reference><Citation>Verrijdt G, Haelens A, Claessens F. Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. Mol Genet Metab. 2003;78(3):175&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">12649062</ArticleId></ArticleIdList></Reference><Reference><Citation>van Royen ME, van Cappellen WA, de Vos C, Houtsmuller AB, Trapman J. Stepwise androgen receptor dimerization. J Cell Sci. 2012;125(Pt 8):1970&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22328501</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CI, Zhou ZX, Sar M, Wilson EM. Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. J Biol Chem. 1993;268(25):19004&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8360187</ArticleId></ArticleIdList></Reference><Reference><Citation>van Royen ME, Cunha SM, Brink MC, Mattern KA, Nigg AL, Dubbink HJ, et al. Compartmentalization of androgen receptor protein-protein interactions in living cells. J Cell Biol. 2007;177(1):63&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064112</ArticleId><ArticleId IdType="pubmed">17420290</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou ZX, Sar M, Simental JA, Lane MV, Wilson EM. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J Biol Chem. 1994;269(18):13115&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">8175737</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutress ML, Whitaker HC, Mills IG, Stewart M, Neal DE. Structural basis for the nuclear import of the human androgen receptor. J Cell Sci. 2008;121(Pt 7):957&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">18319300</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenmakers E, Alen P, Verrijdt G, Peeters B, Verhoeven G, Rombauts W, et al. Differential DNA binding by the androgen and glucocorticoid receptors involves the second Zn-finger and a C-terminal extension of the DNA-binding domains. Biochem J. 1999;341(Pt 3):515&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1220386</ArticleId><ArticleId IdType="pubmed">10417312</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinckemalie L, Vanderschueren D, Boonen S, Claessens F. The hinge region in androgen receptor control. Mol Cell Endocrinol. 2012;358(1):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22406839</ArticleId></ArticleIdList></Reference><Reference><Citation>Haelens A, Tanner T, Denayer S, Callewaert L, Claessens F. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res. 2007;67(9):4514&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17483368</ArticleId></ArticleIdList></Reference><Reference><Citation>Farla P, Hersmus R, Geverts B, Mari PO, Nigg AL, Dubbink HJ, et al. The androgen receptor ligand-binding domain stabilizes DNA binding in living cells. J Struct Biol. 2004;147(1):50&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">15109605</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanner TM, Denayer S, Geverts B, Van Tilborgh N, Kerkhofs S, Helsen C, et al. A 629RKLKK633 motif in the hinge region controls the androgen receptor at multiple levels. Cell Mol Life Sci. 2010;67(11):1919&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">20186458</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe9;tivier R, Penot G, H&#xfc;bner MR, Reid G, Brand H, Kos M, et al. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell. 2003;115(6):751&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">14675539</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu M, Liu M, Sauve AA, Jiao X, Zhang X, Wu X, et al. Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol. 2006;26(21):8122&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1636736</ArticleId><ArticleId IdType="pubmed">16923962</ArticleId></ArticleIdList></Reference><Reference><Citation>Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D, et al. A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol. 1996;3(1):87&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">8548460</ArticleId></ArticleIdList></Reference><Reference><Citation>Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997;387(6634):733&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9192902</ArticleId></ArticleIdList></Reference><Reference><Citation>Heldring N, Pawson T, McDonnell D, Treuter E, Gustafsson JA, Pike AC. Structural insights into corepressor recognition by antagonist-bound estrogen receptors. J Biol Chem. 2007;282(14):10449&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">17283072</ArticleId></ArticleIdList></Reference><Reference><Citation>He B, Lee LW, Minges JT, Wilson EM. Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction. J Biol Chem. 2002;277(28):25631&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12000757</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadal M, Prekovic S, Gallastegui N, Helsen C, Abella M, Zielinska K, et al. Structure of the homodimeric androgen receptor ligand-binding domain. Nat Commun. 2017;8:14388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5303882</ArticleId><ArticleId IdType="pubmed">28165461</ArticleId></ArticleIdList></Reference><Reference><Citation>Christiaens V, Bevan CL, Callewaert L, Haelens A, Verrijdt G, Rombauts W, et al. Characterization of the two coactivator-interacting surfaces of the androgen receptor and their relative role in transcriptional control. J Biol Chem. 2002;277(51):49230&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12370175</ArticleId></ArticleIdList></Reference><Reference><Citation>Callewaert L, Verrijdt G, Christiaens V, Haelens A, Claessens F. Dual function of an amino-terminal amphipatic helix in androgen receptor-mediated transactivation through specific and nonspecific response elements. J Biol Chem. 2003;278(10):8212&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12509416</ArticleId></ArticleIdList></Reference><Reference><Citation>Saporita AJ, Zhang Q, Navai N, Dincer Z, Hahn J, Cai X, et al. Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. J Biol Chem. 2003;278(43):41998&#x2013;2005.</Citation><ArticleIdList><ArticleId IdType="pubmed">12923188</ArticleId></ArticleIdList></Reference><Reference><Citation>Poukka H, Karvonen U, Yoshikawa N, Tanaka H, Palvimo JJ, J&#xe4;nne OA. The RING finger protein SNURF modulates nuclear trafficking of the androgen receptor. Journal of Cell Science. 2000;113(Pt 17):2991&#x2013;3001.</Citation><ArticleIdList><ArticleId IdType="pubmed">10934038</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyagi RK, Lavrovsky Y, Ahn SC, Song CS, Chatterjee B, Roy AK. Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol Endocrinol. 2000;14(8):1162&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">10935541</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt WB, Welsh MJ. Chaperone functions of the heat shock proteins associated with steroid receptors. Semin Cell Biol. 1994;5(2):83&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">7915146</ArticleId></ArticleIdList></Reference><Reference><Citation>Cano LQ, Lavery DN, Bevan CL. Mini-review: Foldosome regulation of androgen receptor action in prostate cancer. Mol Cell Endocrinol. 2013;369(1&#x2013;2):52&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">23395916</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y, Fliss AE, Robins DM, Caplan AJ. Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem. 1996;271(45):28697&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">8910505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni L, Llewellyn R, Kesler CT, Kelley JB, Spencer A, Snow CJ, et al. Androgen induces a switch from cytoplasmic retention to nuclear import of the androgen receptor. Mol Cell Biol. 2013;33(24):4766&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3889559</ArticleId><ArticleId IdType="pubmed">24100013</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;kel S, Mingot JM, Schwarzmaier P, Hartmann E, G&#xf6;rlich D. Importins fulfil a dual function as nuclear import receptors and cytoplasmic chaperones for exposed basic domains. EMBO J. 2002;21(3):377&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125346</ArticleId><ArticleId IdType="pubmed">11823430</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Kim HJ, Wang H, Monaghan J, Freyermuth F, Sung JC, et al. Nuclear-import receptors reverse aberrant phase transitions of RNA-binding proteins with prion-like domains. Cell. 2018;173(3):677&#x2013;92.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911940</ArticleId><ArticleId IdType="pubmed">29677512</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemppainen JA, Lane MV, Sar M, Wilson EM. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem. 1992;267(2):968&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">1730684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswamy S, Weinbauer GF. Endocrine control of spermatogenesis: role of FSH and LH/ testosterone. Spermatogenesis. 2014;4(2):e996025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4581062</ArticleId><ArticleId IdType="pubmed">26413400</ArticleId></ArticleIdList></Reference><Reference><Citation>Grino PB, Griffin JE, Wilson JD. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology. 1990;126(2):1165&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">2298157</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzouni F, Godoy A, Li Y, Mohler J. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol. 2012;2012:530121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3253436</ArticleId><ArticleId IdType="pubmed">22235201</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamana K, Labrie F, Luu-The V. Human type 3 5&#x3b1;-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. Horm Mol Biol Clin Investig. 2010;2(3):293&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25961201</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CY, McDonnell DP. Androgen receptor-cofactor interactions as targets for new drug discovery. Trends Pharmacol Sci. 2005;26(5):225&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15860367</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Wang D, Dar JA, Singh P, Graham L, Liu W, et al. Nuclear export signal of androgen receptor (NESAR) regulation of androgen receptor level in human prostate cell lines via ubiquitination and proteasome-dependent degradation. Endocrinology. 2012;153(12):5716&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3512072</ArticleId><ArticleId IdType="pubmed">23041672</ArticleId></ArticleIdList></Reference><Reference><Citation>Black BE, Holaska JM, Rastinejad F, Paschal BM. DNA binding domains in diverse nuclear receptors function as nuclear export signals. Curr Biol. 2001;11(22):1749&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">11719216</ArticleId></ArticleIdList></Reference><Reference><Citation>Black BE, Vitto MJ, Gioeli D, Spencer A, Afshar N, Conaway MR, et al. Transient, ligand-dependent arrest of the androgen receptor in subnuclear foci alters phosphorylation and coactivator interactions. Mol Endocrinol. 2004;18(4):834&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">14684849</ArticleId></ArticleIdList></Reference><Reference><Citation>Gioeli D, Black BE, Gordon V, Spencer A, Kesler CT, Eblen ST, et al. Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol. 2006;20(3):503&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">16282370</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Kesler CT, Paschal BM, Balk SP. Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1. J Biol Chem. 2009;284(38):25576&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757959</ArticleId><ArticleId IdType="pubmed">19622840</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold FJ, Pluciennik A, Merry DE. Impaired nuclear export of polyglutamine-expanded androgen receptor in spinal and bulbar muscular atrophy. Sci Rep. 2019;9(1):119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6333819</ArticleId><ArticleId IdType="pubmed">30644418</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitworth H, Bhadel S, Ivey M, Conaway M, Spencer A, Hernan R, et al. Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen. PLoS One. 2012;7(6):e38950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3384611</ArticleId><ArticleId IdType="pubmed">22761715</ArticleId></ArticleIdList></Reference><Reference><Citation>Shank LC, Kelley JB, Gioeli D, Yang CS, Spencer A, Allison LA, et al. Activation of the DNA-dependent protein kinase stimulates nuclear export of the androgen receptor in vitro. J Biol Chem. 2008;283(16):10568&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7486792</ArticleId><ArticleId IdType="pubmed">18270197</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies P, Watt K, Kelly SM, Clark C, Price NC, McEwan IJ. Consequences of poly-glutamine repeat length for the conformation and folding of the androgen receptor amino-terminal domain. J Mol Endocrinol. 2008;41(5):301&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">18762554</ArticleId></ArticleIdList></Reference><Reference><Citation>Escobedo A, Topal B, Kunze MBA, Aranda J, Chiesa G, Mungianu D, et al. Side chain to main chain hydrogen bonds stabilize a polyglutamine helix in a transcription factor. Nat Commun. 2019;10(1):2034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6497633</ArticleId><ArticleId IdType="pubmed">31048691</ArticleId></ArticleIdList></Reference><Reference><Citation>Eftekharzadeh B, Piai A, Chiesa G, Mungianu D, Garc&#xed;a J, Pierattelli R, et al. Sequence context influences the structure and aggregation behavior of a polyQ tract. Biophys J. 2016;110(11):2361&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900447</ArticleId><ArticleId IdType="pubmed">27276254</ArticleId></ArticleIdList></Reference><Reference><Citation>Masino L, Pastore A. A structural approach to trinucleotide expansion diseases. Brain Res Bull. 2001;56(3&#x2013;4):183&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11719249</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzolo I, Gliozzi A, Rusmini P, Sau D, Crippa V, Simonini F, et al. The role of the polyglutamine tract in androgen receptor. J Steroid Biochem Mol Biol. 2008;108(3&#x2013;5):245&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17945479</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider R, Schumacher MC, Mueller H, Nand D, Klaukien V, Heise H, et al. Structural characterization of polyglutamine fibrils by solid-state NMR spectroscopy. J Mol Biol. 2011;412(1):121&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">21763317</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchanan LE, Carr JK, Fluitt AM, Hoganson AJ, Moran SD, de Pablo JJ, et al. Structural motif of polyglutamine amyloid fibrils discerned with mixed-isotope infrared spectroscopy. Proc Natl Acad Sci U S A. 2014;111(16):5796&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000827</ArticleId><ArticleId IdType="pubmed">24550484</ArticleId></ArticleIdList></Reference><Reference><Citation>Perutz MF, Johnson T, Suzuki M, Finch JT. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A. 1994;91(12):5355&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC43993</ArticleId><ArticleId IdType="pubmed">8202492</ArticleId></ArticleIdList></Reference><Reference><Citation>Perutz MF, Pope BJ, Owen D, Wanker EE, Scherzinger E. Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of Sup35 and of the amyloid beta-peptide of amyloid plaques. Proc Natl Acad Sci U S A. 2002;99(8):5596&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122815</ArticleId><ArticleId IdType="pubmed">11960015</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman AP, Harmison G, Strand AD, Olson JM, Fischbeck KH. Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum Mol Genet. 2002;11(17):1967&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165558</ArticleId></ArticleIdList></Reference><Reference><Citation>Zboray L, Pluciennik A, Curtis D, Liu Y, Berman-Booty LD, Orr C, et al. Preventing the androgen receptor N/C interaction delays disease onset in a mouse model of SBMA. Cell Rep. 2015;13(10):2312&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4684905</ArticleId><ArticleId IdType="pubmed">26673324</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr CR, Montie HL, Liu Y, Bolzoni E, Jenkins SC, Wilson EM, et al. An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. J Biol Chem. 2010;285(46):35567&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2975181</ArticleId><ArticleId IdType="pubmed">20826791</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou ZX, Kemppainen JA, Wilson EM. Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol Endocrinol. 1995;9(5):605&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">7565807</ArticleId></ArticleIdList></Reference><Reference><Citation>Langley E, Kemppainen JA, Wilson EM. Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J Biol Chem. 1998;273(1):92&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">9417052</ArticleId></ArticleIdList></Reference><Reference><Citation>Montie HL, Pestell RG, Merry DE. SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA. J Neurosci. 2011;31(48):17425&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6088793</ArticleId><ArticleId IdType="pubmed">22131404</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaramuzzino C, Casci I, Parodi S, Lievens PMJ, Polanco MJ, Milioto C, et al. Protein arginine methyltransferase 6 enhances polyglutamine-expanded androgen receptor function and toxicity in spinal and bulbar muscular atrophy. Neuron. 2015;85(1):88&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4305189</ArticleId><ArticleId IdType="pubmed">25569348</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzolo I, Burnett BG, Young JE, Brenne PL, La Spada AR, Fischbeck KH, et al. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum Mol Genet. 2007;16(13):1593&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">17470458</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzolo I, Stack C, Kong L, Musaro A, Adachi H, Katsuno M, et al. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron. 2009;63(3):316&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735765</ArticleId><ArticleId IdType="pubmed">19679072</ArticleId></ArticleIdList></Reference><Reference><Citation>Polanco MJ, Parodi S, Piol D, Stack C, Chivet M, Contestabile A, et al. Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy. Sci Transl Med. 2016;8(370):370ra181.</Citation><ArticleIdList><ArticleId IdType="pubmed">28003546</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFevre-Bernt MA, Ellerby LM. Kennedy&#x2019;s disease. Phosphorylation of the polyglutamine-expanded form of androgen receptor regulates its cleavage by caspase-3 and enhances cell death. J Biol Chem. 2003;278(37):34918&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">12824190</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua JP, Reddy SL, Yu Z, Giorgetti E, Montie HL, Mukherjee S, et al. Disrupting SUMOylation enhances transcriptional function and ameliorates polyglutamine androgen receptor-mediated disease. J Clin Invest. 2015;125(2):831&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4319414</ArticleId><ArticleId IdType="pubmed">25607844</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, Trifiro M. The androgen receptor gene mutations database: 2012 update. Human mutation. 2012;33(5):887&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">22334387</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao H, Yu Z, Wu Y, Nan J, Merry DE, Sekiguchi JM, et al. A polyglutamine expansion disease protein sequesters PTIP to attenuate DNA repair and increase genomic instability. Hum Mol Genet. 2012;21(19):4225&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3441122</ArticleId><ArticleId IdType="pubmed">22736030</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki E, Zhao Y, Ito S, Sawatsubashi S, Murata T, Furutani T, et al. Aberrant E2F activation by polyglutamine expansion of androgen receptor in SBMA neurotoxicity. Proc Natl Acad Sci U S A. 2009;106(10):3818&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656163</ArticleId><ArticleId IdType="pubmed">19237573</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgetti E, Yu Z, Chua JP, Shimamura R, Zhao L, Zhu F, et al. Rescue of metabolic alterations in AR113Q skeletal muscle by peripheral androgen receptor gene silencing. Cell Rep. 2016;17(1):125&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5076565</ArticleId><ArticleId IdType="pubmed">27681426</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgia D, Malena A, Spinazzi M, Desbats MA, Salviati L, Russell AP, et al. Increased mitophagy in the skeletal muscle of spinal and bulbar muscular atrophy patients. Hum Mol Genet. 2017;26(6):1087&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5409076</ArticleId><ArticleId IdType="pubmed">28087734</ArticleId></ArticleIdList></Reference><Reference><Citation>Belikov S, Bott LC, Fischbeck KH, Wrange &#xd6;. The polyglutamine-expanded androgen receptor has increased DNA binding and reduced transcriptional activity. Biochem Biophys Rep. 2015;3:134&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5668691</ArticleId><ArticleId IdType="pubmed">29124176</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR, Coetzee GA. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet. 2000;9(2):267&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">10607837</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima H, Kimura F, Nakagawa T, Furutama D, Shinoda K, Shimizu A, et al. Transcriptional activation by the androgen receptor in X-linked spinal and bulbar muscular atrophy. J Neurol Sci. 1996;142(1&#x2013;2):12&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8902713</ArticleId></ArticleIdList></Reference><Reference><Citation>Choong CS, Kemppainen JA, Zhou ZX, Wilson EM. Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol Endocrinol. 1996;10(12):1527&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">8961263</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA, et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res. 1997;57(6):1194&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9067292</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheppard RL, Spangenburg EE, Chin ER, Roth SM. Androgen receptor polyglutamine repeat length affects receptor activity and C2C12 cell development. Physiol Genomics. 2011;43(20):1135&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3217329</ArticleId><ArticleId IdType="pubmed">21828246</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao PW, Lin DL, Nakao R, Chang C. The linkage of Kennedy&#x2019;s neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator. J Biol Chem. 1999;274(29):20229&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">10400640</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer NW, C&#xe9;raline J, Hartl FU, Broadley SA. N-terminal polyglutamine-containing fragments inhibit androgen receptor transactivation function. Biol Chem. 2008;389(12):1455&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">18844449</ArticleId></ArticleIdList></Reference><Reference><Citation>Adachi H, Katsuno M, Minamiyama M, Waza M, Sang C, Nakagomi Y, et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain. 2005;128(Pt 3):659&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">15659427</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Nakagomi Y, Kobayashi Y, Merry DE, Tanaka F, Doyu M, et al. Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. Am J Pathol. 1998;153(3):695&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853004</ArticleId><ArticleId IdType="pubmed">9736019</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenoien DL, Cummings CJ, Adams HP, Mancini MG, Patel K, DeMartino GN, et al. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum Mol Genet. 1999;8(5):731&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">10196362</ArticleId></ArticleIdList></Reference><Reference><Citation>Jochum T, Ritz ME, Schuster C, Funderburk SF, Jehle K, Schmitz K, et al. Toxic and non-toxic aggregates from the SBMA and normal forms of androgen receptor have distinct oligomeric structures. Biochim Biophys Acta. 2012;1822(6):1070&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22366762</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss A, Klein C, Woodman B, Sathasivam K, Bibel M, R&#xe9;gulier E, et al. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington&#x2019;s disease. J Neurochem. 2008;104(3):846&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">17986219</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag EM, Lotz GP, Yang G, Sontag CJ, Cummings BJ, Glabe CG, et al. Detection of mutant huntingtin aggregation conformers and modulation of SDS-soluble fibrillar oligomers by small molecules. J Huntingtons Dis. 2012;1(1):119&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786168</ArticleId><ArticleId IdType="pubmed">24086178</ArticleId></ArticleIdList></Reference><Reference><Citation>Sontag EM, Lotz GP, Agrawal N, Tran A, Aron R, Yang G, et al. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington&#x2019;s disease models. J Neurosci. 2012;32(32):11109&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3546821</ArticleId><ArticleId IdType="pubmed">22875942</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger TR, Montie HL, Jain P, Legleiter J, Merry DE. Identification of novel polyglutamine-expanded aggregation species in spinal and bulbar muscular atrophy. Brain Res. 2015;1628(Pt B):254&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4681586</ArticleId><ArticleId IdType="pubmed">26453288</ArticleId></ArticleIdList></Reference><Reference><Citation>Heine EM, Berger TR, Pluciennik A, Orr CR, Zboray L, Merry DE. Proteasome-mediated proteolysis of the polyglutamine-expanded androgen receptor is a late event in spinal and bulbar muscular atrophy (SBMA) pathogenesis. J Biol Chem. 2015;290(20):12572&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4432278</ArticleId><ArticleId IdType="pubmed">25795778</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller J, Arrasate M, Brooks E, Libeu CP, Legleiter J, Hatters D, et al. Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat Chem Biol. 2011;7(12):925&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3271120</ArticleId><ArticleId IdType="pubmed">22037470</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Chevalier-Larsen ES, Merry DE, Diamond MI. Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy. J Biol Chem. 2007;282(5):3157&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">17121819</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedelsky NB, Pennuto M, Smith RB, Palazzolo I, Moore J, Nie Z, et al. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron. 2010;67(6):936&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514079</ArticleId><ArticleId IdType="pubmed">20869592</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431(7010):805&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">15483602</ArticleId></ArticleIdList></Reference><Reference><Citation>McCampbell A, Taylor JP, Taye AA, Robitschek J, Li M, Walcott J, et al. CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet. 2000;9(14):2197&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">10958659</ArticleId></ArticleIdList></Reference><Reference><Citation>Adachi H, Katsuno M, Minamiyama M, Sang C, Pagoulatos G, Angelidis C, et al. Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J Neurosci. 2003;23(6):2203&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742038</ArticleId><ArticleId IdType="pubmed">12657679</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi Y, Kume A, Li M, Doyu M, Hata M, Ohtsuka K, et al. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J Biol Chem. 2000;275(12):8772&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10722721</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CK, Andriola IF, Kampinga HH, Merry DE. Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Hum Mol Genet. 2002;11(5):515&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">11875046</ArticleId></ArticleIdList></Reference><Reference><Citation>Yersak JM, Montie HL, Chevalier-Larsen ES, Liu Y, Huang L, Rechsteiner M, et al. The 11S proteasomal activator REG&#x3b3; impacts polyglutamine-expanded androgen receptor aggregation and motor neuron viability through distinct mechanisms. Front Mol Neurosci. 2017;10:159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5442185</ArticleId><ArticleId IdType="pubmed">28596723</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel A, Walcott J, Woods J, Duda J, Merry DE. Expression of expanded repeat androgen receptor produces neurologic disease in transgenic mice. Hum Mol Genet. 2001;10(2):107&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">11152658</ArticleId></ArticleIdList></Reference><Reference><Citation>Walcott JL, Merry DE. Ligand promotes intranuclear inclusions in a novel cell model of spinal and bulbar muscular atrophy. J Biol Chem. 2002;277(52):50855&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12388541</ArticleId></ArticleIdList></Reference><Reference><Citation>Montie HL, Cho MS, Holder L, Liu Y, Tsvetkov AS, Finkbeiner S, et al. Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet. 2009;18(11):1937&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678926</ArticleId><ArticleId IdType="pubmed">19279159</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BP, Paulson HL, Merry DE, Salazar-Grueso EF, Brinkmann AO, Wilson EM, et al. Characterization of an expanded glutamine repeat androgen receptor in a neuronal cell culture system. Neurobiol Dis. 1997;3(4):313&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">9173928</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar-Grueso EF, Kim S, Kim H. Embryonic mouse spinal cord motor neuron hybrid cells. Neuroreport. 1991;2(9):505&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1751804</ArticleId></ArticleIdList></Reference><Reference><Citation>Simeoni S, Mancini MA, Stenoien DL, Marcelli M, Weigel NL, Zanisi M, et al. Motoneuronal cell death is not correlated with aggregate formation of androgen receptors containing an elongated polyglutamine tract. Hum Mol Genet. 2000;9(1):133&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10587588</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P, Sau D, Crippa V, Palazzolo I, Simonini F, Onesto E, et al. Aggregation and proteasome: the case of elongated polyglutamine aggregation in spinal and bulbar muscular atrophy. Neurobiol Aging. 2007;28(7):1099&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">16781019</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusmini P, Crippa V, Giorgetti E, Boncoraglio A, Cristofani R, Carra S, et al. Clearance of the mutant androgen receptor in motoneuronal models of spinal and bulbar muscular atrophy. Neurobiol Aging. 2013;34(11):2585&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748343</ArticleId><ArticleId IdType="pubmed">23810450</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortes CJ, Miranda HC, Frankowski H, Batlevi Y, Young JE, Le A, et al. Polyglutamine-expanded androgen receptor interferes with TFEB to elicit autophagy defects in SBMA. Nat Neurosci. 2014;17(9):1180&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4180729</ArticleId><ArticleId IdType="pubmed">25108912</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman AP, Yu Z, Murray S, Peralta R, Low A, Guo S, et al. Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep. 2014;7(3):774&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4356525</ArticleId><ArticleId IdType="pubmed">24746732</ArticleId></ArticleIdList></Reference><Reference><Citation>Milioto C, Malena A, Maino E, Polanco MJ, Marchioretti C, Borgia D, et al. Beta-agonist stimulation ameliorates the phenotype of spinal and bulbar muscular atrophy mice and patient-derived myotubes. Sci Rep. 2017;7:41046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5259768</ArticleId><ArticleId IdType="pubmed">28117338</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijikata Y, Katsuno M, Suzuki K, Hashizume A, Araki A, Yamada S, et al. Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy. Ann Clin Transl Neurol. 2016;3(7):537&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4931718</ArticleId><ArticleId IdType="pubmed">27386502</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunseich C, Zukosky K, Kats IR, Ghosh L, Harmison GG, Bott LC, et al. Stem cell-derived motor neurons from spinal and bulbar muscular atrophy patients. Neurobiol Dis. 2014;70:12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172362</ArticleId><ArticleId IdType="pubmed">24925468</ArticleId></ArticleIdList></Reference><Reference><Citation>Dossena M, Bedini G, Rusmini P, Giorgetti E, Canazza A, Tosetti V, et al. Human adipose-derived mesenchymal stem cells as a new model of spinal and bulbar muscular atrophy. PLoS One. 2014;9(11):e112746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4231043</ArticleId><ArticleId IdType="pubmed">25392924</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheila M, Narayanan G, Ma S, Tam WL, Chai J, Stanton LW. Phenotypic and molecular features underlying neurodegeneration of motor neurons derived from spinal and bulbar muscular atrophy patients. Neurobiol Dis. 2019;124:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">30391288</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeyama K, Ito S, Yamamoto A, Tanimoto H, Furutani T, Kanuka H, et al. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron. 2002;35(5):855&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372281</ArticleId></ArticleIdList></Reference><Reference><Citation>Badders NM, Korff A, Miranda HC, Vuppala PK, Smith RB, Winborn BJ, et al. Selective modulation of the androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy. Nat Med. 2018;24(4):427&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5975249</ArticleId><ArticleId IdType="pubmed">29505030</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron. 2002;35(5):843&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevalier-Larsen ES, O&#x2019;Brien CJ, Wang H, Jenkins SC, Holder L, Lieberman AP, et al. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci. 2004;24(20):4778&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729468</ArticleId><ArticleId IdType="pubmed">15152038</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Peterson KR, Meadows SA, McClain ME, Jeng G, Chmelar RS, et al. Androgen receptor YAC transgenic mice carrying CAG 45 alleles show trinucleotide repeat instability. Hum Mol Genet. 1998;7(6):959&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">9580659</ArticleId></ArticleIdList></Reference><Reference><Citation>Sopher BL, Thomas PS, LaFevre-Bernt MA, Holm IE, Wilke SA, Ware CB, et al. Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron. 2004;41(5):687&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">15003169</ArticleId></ArticleIdList></Reference><Reference><Citation>Monks DA, Johansen JA, Mo K, Rao P, Eagleson B, Yu Z, et al. Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc Natl Acad Sci U S A. 2007;104(46):18259&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2084330</ArticleId><ArticleId IdType="pubmed">17984063</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, She WC, Luchak JM, Martinez P, et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature. 2000;408(6808):101&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11081516</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Dadgar N, Albertelli M, Scheller A, Albin RL, Robins DM, et al. Abnormalities of germ cell maturation and sertoli cell cytoskeleton in androgen receptor 113 CAG knock-in mice reveal toxic effects of the mutant protein. Am J Pathol. 2006;168(1):195&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1592669</ArticleId><ArticleId IdType="pubmed">16400023</ArticleId></ArticleIdList></Reference><Reference><Citation>Albertelli MA, Scheller A, Brogley M, Robins DM. Replacing the mouse androgen receptor with human alleles demonstrates glutamine tract length-dependent effects on physiology and tumorigenesis in mice. Mol Endocrinol. 2006;20(6):1248&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">16601069</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Dadgar N, Albertelli M, Gruis K, Jordan C, Robins DM, et al. Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J Clin Invest. 2006;116(10):2663&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1564432</ArticleId><ArticleId IdType="pubmed">16981011</ArticleId></ArticleIdList></Reference><Reference><Citation>Latimer CS, Flanagan ME, Cimino PJ, Jayadev S, Davis M, Hoffer ZS, et al. Neuropathological comparison of adult onset and juvenile Huntington&#x2019;s disease with cerebellar atrophy: a report of a father and son. J Huntingtons Dis. 2017;6(4):337&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5832043</ArticleId><ArticleId IdType="pubmed">29036832</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Banno H, Suzuki K, Takeuchi Y, Kawashima M, Yabe I, et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(9):875&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">20691641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Suzuki K, Hirakawa A, Hijikata Y, Yamada S, et al. Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled study. J Neurol Neurosurg Psychiatry. 2017;88(12):1026&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">28780536</ArticleId></ArticleIdList></Reference><Reference><Citation>Banno H, Katsuno M, Suzuki K, Takeuchi Y, Kawashima M, Suga N, et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol. 2009;65(2):140&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">19259967</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt BJ, Greenberg CR, Allingham-Hawkins DJ, Spriggs EL. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology. 2002;59(5):770&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">12221177</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Doyu M, Minamiyama M, Sang C, Kobayashi Y, et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med. 2003;9(6):768&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">12754502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson AC, Meethal SV, Bowen RL, Atwood CS. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Investig Drugs. 2007;16(11):1851&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">17970643</ArticleId></ArticleIdList></Reference><Reference><Citation>Tindall DJ, Rittmaster RS. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol. 2008;179(4):1235&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667246</ArticleId><ArticleId IdType="pubmed">18280514</ArticleId></ArticleIdList></Reference><Reference><Citation>Toren P, Margel D, Kulkarni G, Finelli A, Zlotta A, Fleshner N. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study. BMJ. 2013;346:f2109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3626257</ArticleId><ArticleId IdType="pubmed">23587564</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrader JA, Kats I, Kokkinis A, Zampieri C, Levy E, Joe GO, et al. A randomized controlled trial of exercise in spinal and bulbar muscular atrophy. Ann Clin Transl Neurol. 2015;2(7):739&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4531056</ArticleId><ArticleId IdType="pubmed">26273686</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotkine M, Friedlander Y, Hochner H. Triathletes are over-represented in a population of patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7&#x2013;8):534&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25007701</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Wicks P, Brownstein CA, Massagli MP, Toronjo M, Talbot K, et al. Concordance between site of onset and limb dominance in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82(8):853&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">20562391</ArticleId></ArticleIdList></Reference><Reference><Citation>Drory VE, Goltsman E, Reznik JG, Mosek A, Korczyn AD. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2001;191(1&#x2013;2):133&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11677004</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Haas VD, Florence JM, Kloos AD, Scheirbecker J, Lopate G, Hayes SM, et al. A randomized controlled trial of resistance exercise in individuals with ALS. Neurology. 2007;68(23):2003&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548549</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz AJ, Brasel JA, Hintz RL, Mohan S, Cooper DM. Acute effect of brief low- and high-intensity exercise on circulating insulin-like growth factor (IGF) I, II, and IGF-binding protein-3 and its proteolysis in young healthy men. J Clin Endocrinol Metab. 1996;81(10):3492&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8855791</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi C, Bott LC, Chen KL, Harmison GG, Katsuno M, Sobue G, et al. Insulinlike growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy. Mol Med. 2012;18:1261&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3521783</ArticleId><ArticleId IdType="pubmed">22952056</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlqvist JR, Vissing J. Exercise therapy in spinobulbar muscular atrophy and other neuromuscular disorders. J Mol Neurosci. 2016;58(3):388&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">26585990</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunseich C, Miller R, Swan T, Glass DJ, Mouelhi ME, Fornaro M, et al. Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial. Lancet Neurol. 2018. 17:1043-1052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6415539</ArticleId><ArticleId IdType="pubmed">30337273</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan C, Ren H, Gao S. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins: roles in skeletal muscle growth and differentiation. Gen Comp Endocrinol. 2010;167(3):344&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">20403355</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar BK, Llad&#xf3; J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003;301(5634):839&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">12907804</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G, Giacinti C, Pelosi L, Nicoletti C, Winn N, Barberi L, et al. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol. 2005;168(2):193&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171577</ArticleId><ArticleId IdType="pubmed">15657392</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijikata Y, Katsuno M, Suzuki K, Hashizume A, Araki A, Yamada S, et al. Treatment with creatine monohydrate in spinal and bulbar muscular atrophy: protocol for a randomized, double-blind, placebo-controlled trial. JMIR Res Protoc. 2018;7(3):e69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5859194</ArticleId><ArticleId IdType="pubmed">29506970</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Banno H, Suzuki K, Suga N, Mano T, et al. Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain. 2012;135(Pt 9):2838&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">22773541</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000;80(3):1107&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">10893433</ArticleId></ArticleIdList></Reference><Reference><Citation>Sant'Ana Pereira JA, Sargeant AJ, Rademaker AC, de Haan A, van Mechelen W. Myosin heavy chain isoform expression and high energy phosphate content in human muscle fibres at rest and post-exercise. J Physiol. 1996;496(Pt 2):583&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1160901</ArticleId><ArticleId IdType="pubmed">8910240</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada S, Hashizume A, Hijikata Y, Inagaki T, Suzuki K, Kondo N, et al. Decreased peak expiratory flow associated with muscle fiber-type switching in spinal and bulbar muscular atrophy. PLoS One. 2016;11(12):e0168846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5179045</ArticleId><ArticleId IdType="pubmed">28005993</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocchi A, Milioto C, Parodi S, Armirotti A, Borgia D, Pellegrini M, et al. Glycolytic-to-oxidative fiber-type switch and mTOR signaling activation are early-onset features of SBMA muscle modified by high-fat diet. Acta Neuropathol. 2016;132(1):127&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4911374</ArticleId><ArticleId IdType="pubmed">26971100</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee B, Sharma U, Balasubramanian K, Kalaivani M, Kalra V, Jagannathan NR. Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: a randomized, placebo-controlled 31P MRS study. Magn Reson Imaging. 2010;28(5):698&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">20395096</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter MC, Lochm&#xfc;ller H, Reilich P, Klopstock T, Huber R, Hartard M, et al. Creatine monohydrate in muscular dystrophies: a double-blind, placebo-controlled clinical study. Neurology. 2000;54(9):1848&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">10802796</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarnopolsky MA, Mahoney DJ, Vajsar J, Rodriguez C, Doherty TJ, Roy BD, et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology. 2004;62(10):1771&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15159476</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Halievski K, Katsuno M, Adachi H, Sobue G, Breedlove SM, et al. Pre-clinical symptoms of SBMA may not be androgen-dependent: implications from two SBMA mouse models. Hum Mol Genet. 2018;27(14):2425&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6030880</ArticleId><ArticleId IdType="pubmed">29897452</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold AP, Gorski RA. Gonadal steroid induction of structural sex differences in the central nervous system. Annu Rev Neurosci. 1984;7:413&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">6370082</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahashi K, Katsuno M, Hung G, Adachi H, Kondo N, Nakatsuji H, et al. Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet. 2015;24(21):5985&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">26231218</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara H, Kanda F, Nishio H, Sumino K, Chihara K. Clinical features and skewed X-chromosome inactivation in female carriers of X-linked recessive spinal and bulbar muscular atrophy. J Neurol. 2001;248(10):856&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">11697521</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanman TA, Bakar D, Badders NM, Burke A, Kokkinis A, Shrader JA, et al. Sexual reassignment fails to prevent Kennedy&#x2019;s disease. J Neuromuscul Dis. 2016;3(1):121&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27854206</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijikata Y, Hashizume A, Yamada S, Ito D, Banno H, Suzuki K, et al. Long-term effects of androgen deprivation in a patient with spinal and bulbar muscular atrophy&#x2014;a case report with 14 years of follow-up. Intern Med. 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6709315</ArticleId><ArticleId IdType="pubmed">30996158</ArticleId></ArticleIdList></Reference><Reference><Citation>Mhaouty-Kodja S. Role of the androgen receptor in the central nervous system. Mol Cell Endocrinol. 2018;465:103&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">28826929</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Cantle JP, Chatzopoulou D, Wang N, Gao F, Al-Ramahi I, et al. Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. Nat Neurosci. 2016;19(4):623&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5984042</ArticleId><ArticleId IdType="pubmed">26900923</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka F, Reeves MF, Ito Y, Matsumoto M, Li M, Miwa S, et al. Tissue-specific somatic mosaicism in spinal and bulbar muscular atrophy is dependent on CAG-repeat length and androgen receptor&#x2013;gene expression level. Am J Hum Genet. 1999;65(4):966&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288267</ArticleId><ArticleId IdType="pubmed">10486315</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennuto M, Basso M. In vitro and in vivo modeling of spinal and bulbar muscular atrophy. J Mol Neurosci. 2016;58(3):365&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">26614347</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>